MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Gross Profit 2011-2026 | CALT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Quarterly Gross Profit Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.1 M | 49.1 M | 49.1 M |
Gross Profit of other stocks in the Drug manufacturers industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-616 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-1.43 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
57.8 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
86.4 M | $ 19.0 | -1.35 % | $ 122 M | USA |
 |
Agile Therapeutics
AGRX
|
10.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
69.9 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
26.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
154 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
28.8 M | $ 3.1 | - | $ 43.6 M | USA |
 |
HEXO Corp.
HEXO
|
-75.7 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Cronos Group
CRON
|
-25.8 M | $ 2.56 | -0.78 % | $ 1.35 B | Canada |
 |
Bausch Health Companies
BHC
|
6.25 B | $ 5.2 | -3.7 % | $ 1.9 B | Canada |
 |
Aurora Cannabis
ACB
|
188 M | $ 3.39 | -1.6 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
79.5 M | $ 0.99 | -3.18 % | $ 106 M | Canada |
 |
Harrow Health
HROW
|
204 M | $ 34.6 | -1.51 % | $ 1.27 B | USA |
 |
Catalent
CTLT
|
953 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
25.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
135 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
1.35 B | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
197 M | $ 4.02 | -3.37 % | $ 259 M | USA |
 |
Emergent BioSolutions
EBS
|
318 M | $ 7.96 | -1.73 % | $ 408 M | USA |
 |
Evoke Pharma
EVOK
|
-63.7 K | - | - | $ 36.6 M | USA |
 |
OrganiGram Holdings
OGI
|
47.5 M | $ 1.37 | -1.09 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
366 M | $ 2.49 | 11.16 % | $ 328 M | USA |
 |
Pacira BioSciences
PCRX
|
314 M | $ 22.08 | -0.88 % | $ 1.02 B | USA |
 |
Jupiter Wellness
JUPW
|
1.24 M | - | - | $ 33.6 M | USA |
 |
Sundial Growers
SNDL
|
259 M | $ 1.34 | -0.19 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.46 M | $ 2.31 | -0.65 % | $ 2.87 M | USA |
 |
Lannett Company
LCI
|
33.2 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
147 M | $ 6.46 | -3.0 % | $ 3.99 B | Canada |
 |
Veru
VERU
|
5.85 M | $ 2.36 | -1.56 % | $ 318 M | USA |
 |
OptiNose
OPTN
|
41.6 M | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
6.44 B | $ 13.16 | -1.86 % | $ 15.8 B | USA |
 |
PetIQ
PETQ
|
253 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
3.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
70.7 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
221 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
12 M | $ 0.73 | -2.12 % | $ 3.15 M | USA |
 |
Recro Pharma
REPH
|
48.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.09 K | $ 6.69 | -3.04 % | $ 264 M | USA |
 |
Rockwell Medical
RMTI
|
11.7 M | $ 0.96 | -0.73 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
3.58 M | $ 0.9 | -2.12 % | $ 44.9 M | USA |
 |
Zomedica Corp.
ZOM
|
21.7 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
279 K | - | - | $ 55.5 M | USA |
 |
China Pharma Holdings
CPHI
|
-132 K | $ 0.61 | - | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.1 | -4.55 % | $ 24.3 M | USA |